Max Healthcare stock outlook rests on accelerating bed expansion

Published on 11/13/2026 at 02:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Max Healthcare stock is supported by a hospital bed expansion plan and stronger international patient flows. ICICI Securities kept its Buy rating and Rs 1,300 target after the Q2 FY27 update.

Expansion supports hospital growth

ICICI Securities retained its BUY rating and Rs 1,300 target after Max Healthcare's Q2 FY27 update.
New brownfield beds, stronger international demand and a better payor mix support the broker's outlook.
Commissioning costs, oncology pricing pressure and execution risks remain important constraints.

Max Health, INE027H01010, Illustration mit AI erstellt.

Max Healthcare's expansion plan remains central to the investment case after ICICI Securities retained its BUY rating and Rs 1,300 target in a November 4, 2026 results update. DSIJ reported the broker's view on November 12.

The broker expects newly commissioned beds and further brownfield and greenfield additions to support growth over the coming quarters. Max Healthcare added 202 brownfield beds in Q2 FY27 and approved Rs 415 crore of capital expenditure for 209 additional brownfield beds.

Bed additions drive the outlook

According to the DSIJ summary of the ICICI Securities report, gross revenue rose 19.6 percent year over year to Rs 3,209 crore in Q2 FY27, while net revenue increased 18.4 percent to Rs 3,046 crore. EBITDA reached Rs 795 crore, up 18 percent, although the margin was affected by commissioning costs and Rs 17 crore of Kalinga facility upgrade costs.

Operational beds increased 15.9 percent year over year to 5,518, with occupancy at 77 percent. International-patient revenue grew 33 percent and represented 10 percent of revenue. The broker expects the improved payor mix and international flows to offset near-term pressure from oncology drug trade-margin curbs and new greenfield projects.

Risks accompany capacity growth

ICICI Securities estimates that Max Healthcare could add around 1,400 beds across its network over the next three to four quarters. The Gurgaon greenfield hospital is expected to commission 150 to 200 beds by the end of FY27, but management expects an EBITDA drag of Rs 40 crore to Rs 50 crore during the ramp-up.

The broker raised its FY27E and FY28E EBITDA estimates by about 1 percent and 4 percent, respectively. Its main risks include pharmaceutical and medical-supply margin curbs, delays in capacity execution and pricing pressure from institutional business.

Max Healthcare's operating platform

Max Healthcare Institute operates hospitals across India's Delhi-NCR, Haryana, Punjab, Uttarakhand, Maharashtra and Odisha markets. The company also runs MAX@Home, which provides health and wellness services at home, and MAX Lab, which offers pathology services outside its hospital network. The company describes itself as one of India's largest healthcare organizations, with 21 facilities and more than 6,100 beds.